223 related articles for article (PubMed ID: 33068862)
1. Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer.
Yu L; Yang X; Xu C; Sun J; Fang Z; Pan H; Han W
Int Immunopharmacol; 2020 Dec; 89(Pt B):107077. PubMed ID: 33068862
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer.
Yang X; Wei Y; Sheng F; Xu Y; Liu J; Gao L; Yang J; Sun X; Huang J; Guo Q
Aging (Albany NY); 2021 Jul; 13(13):17548-17567. PubMed ID: 34233297
[TBL] [Abstract][Full Text] [Related]
3. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
Weixler B; Cremonesi E; Sorge R; Muraro MG; Delko T; Nebiker CA; Däster S; Governa V; Amicarella F; Soysal SD; Kettelhack C; von Holzen UW; Eppenberger-Castori S; Spagnoli GC; Oertli D; Iezzi G; Terracciano L; Tornillo L; Sconocchia G; Droeser RA
Oncotarget; 2015 Nov; 6(35):37588-99. PubMed ID: 26439988
[TBL] [Abstract][Full Text] [Related]
4. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.
Cabrero-de Las Heras S; Martínez-Balibrea E
World J Gastroenterol; 2018 Nov; 24(42):4738-4749. PubMed ID: 30479461
[TBL] [Abstract][Full Text] [Related]
5. Adenoma to carcinoma: A portrait of molecular and immunological profiles of colorectal sporadic tumors.
Elsayed I; Li L; Sheahan K; Moran B; Bakheit S; Wang X
Int Immunopharmacol; 2021 Nov; 100():108168. PubMed ID: 34562842
[TBL] [Abstract][Full Text] [Related]
6. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
[TBL] [Abstract][Full Text] [Related]
7. Systematic Analysis of CXC Chemokine-Vascular Endothelial Growth Factor A Network in Colonic Adenocarcinoma from the Perspective of Angiogenesis.
Situ Y; Lu X; Cui Y; Xu Q; Deng L; Lin H; Shao Z; Chen J
Biomed Res Int; 2022; 2022():5137301. PubMed ID: 36246978
[TBL] [Abstract][Full Text] [Related]
8. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
Sun X; Chen Q; Zhang L; Chen J; Zhang X
Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533
[TBL] [Abstract][Full Text] [Related]
9. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
Front Immunol; 2021; 12():778329. PubMed ID: 34975867
[TBL] [Abstract][Full Text] [Related]
10. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
Yin Z; Ma T; Chen S; Yu M
Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-36α inhibits colorectal cancer metastasis by enhancing the infiltration and activity of CD8
Wei X; Yao Y; Wang X; Sun J; Zhao W; Qiu L; Zhai W; Qi Y; Gao Y; Wu Y
Int Immunopharmacol; 2021 Nov; 100():108152. PubMed ID: 34555640
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Immunological Role of THBS2 in Colorectal cancer.
Deng B; Liu XP; Wang X
Biomed Res Int; 2021; 2021():1124985. PubMed ID: 34471634
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of CXC subfamily ligands in stage I-III patients with colorectal cancer.
Li X; Zhong Q; Luo D; Du Q; Liu W
PLoS One; 2019; 14(4):e0214611. PubMed ID: 30973890
[TBL] [Abstract][Full Text] [Related]
14. GNA13 promotes tumor growth and angiogenesis by upregulating CXC chemokines via the NF-κB signaling pathway in colorectal cancer cells.
Zhang Z; Tan X; Luo J; Cui B; Lei S; Si Z; Shen L; Yao H
Cancer Med; 2018 Nov; 7(11):5611-5620. PubMed ID: 30267476
[TBL] [Abstract][Full Text] [Related]
15. CXC Chemokines as Therapeutic Targets and Prognostic Biomarkers in Skin Cutaneous Melanoma Microenvironment.
Zhou X; Peng M; He Y; Peng J; Zhang X; Wang C; Xia X; Song W
Front Oncol; 2021; 11():619003. PubMed ID: 33767987
[TBL] [Abstract][Full Text] [Related]
16. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY
Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856
[TBL] [Abstract][Full Text] [Related]
17. ELR+ CXC chemokine expression in benign and malignant colorectal conditions.
Rubie C; Frick VO; Wagner M; Schuld J; Gräber S; Brittner B; Bohle RM; Schilling MK
BMC Cancer; 2008 Jun; 8():178. PubMed ID: 18578857
[TBL] [Abstract][Full Text] [Related]
18. Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis.
Chen E; Qin X; Peng K; Xu X; Li W; Cheng X; Tang C; Cui Y; Wang Z; Liu T
Cell Physiol Biochem; 2018; 45(5):1731-1746. PubMed ID: 29495008
[TBL] [Abstract][Full Text] [Related]
19. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer.
Hojo S; Koizumi K; Tsuneyama K; Arita Y; Cui Z; Shinohara K; Minami T; Hashimoto I; Nakayama T; Sakurai H; Takano Y; Yoshie O; Tsukada K; Saiki I
Cancer Res; 2007 May; 67(10):4725-31. PubMed ID: 17510400
[TBL] [Abstract][Full Text] [Related]
20. The expression and role of CXC chemokines in colorectal cancer.
Verbeke H; Struyf S; Laureys G; Van Damme J
Cytokine Growth Factor Rev; 2011; 22(5-6):345-58. PubMed ID: 22000992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
